Pembrolizumab doubles time to disease progression in patients with advanced colorectal cancer with specific DNA mutations

'Immunotherapies like pembrolizumab have proved to be effective as second-line treatments for advanced disease. Now,... we are starting to see significant efficacy for immunotherapies as first-line treatment for advanced cancers with specific genetic signatures...,' said ASCO President Howard Burris

Like Comment

Front-line therapy with the immune checkpoint inhibitor pembrolizumab (Keytruda) doubled progression-free survival vs chemotherapy in patients with a type of advanced colorectal cancer that has a high number of mutations, which previous research suggests may have a poor prognosis for some patients. This is the first time pembrolizumab has been shown to benefit these patients when used as a front-line therapy.

The findings come from an interim analysis of the phase III KEYNOTE-177 trial that was presented during the virtual scientific programme of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.

Study at a Glance 


 Pembrolizumab as a front-line therapy in patients with microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal carcinoma 


 307 patients with metastatic disease 


 Pembrolizumab improved progression-free survival by 8.3 months 


 Supports pembrolizumab as the new standard of care as first-line therapy 

To view full article and watch the video summary,
register to OnMedica and then click
'View full content'.



Editorial team, Wilmington Healthcare

OnMedica provides high-quality, easy to digest content and CPD for UK-based GPs and clinicians. Our team of expert editors and clinicians develops content across a wide range of topics in a variety of formats—expert articles, bitesize news and quizzes, courses, videos, and more. You can explore OnMedica via the homepage, drop down menu or by typing your topic of choice in the search bar. Why not find out how OnMedica can help you to keep up to date quickly and easily?
3726 Contributions
1 Following